-
Peijia Medical Achieves First Compassionate Use of Taurus Trio TAVR System in Hong Kong
•
Peijia Medical Ltd (HKG: 9996), a leading medical device company, has announced the completion of its first compassionate use case utilizing the Taurus Trio transcatheter aortic valve replacement (TAVR) system in Hong Kong. This milestone marks a significant step in the application of the company’s advanced cardiovascular technology in the…
-
Peijia Medical Secures Exclusive Rights to NowYon’s YonFlow Device in Greater China
•
Peijia Medical Ltd (HKG: 9996) has entered into a licensing agreement with NowYon Medical, securing exclusive rights as the agent for NowYon’s YonFlow blood flow guidance device in Greater China. This eight-year partnership marks a significant collaboration between the two Chinese firms. The YonFlow device, recognized as the world’s first…
-
Edwards Lifesciences to Acquire Peijia Medical’s US Partner JenaValve, Impact on Licensing Deal Minimal
•
China-based Peijia Medical Ltd (HKG: 9996) has announced that its US-based partner JenaValve Technology Inc. will be acquired by Edwards Lifesciences Corporation through a merger agreement. This strategic acquisition comes as part of Edwards Lifesciences’ efforts to strengthen its structural heart portfolio. JenaValve had entered into a licensing agreement with…
-
Peijia Medical’s Taurus Atlas Pro Balloon Dilation Catheter Approved by NMPA for Pulmonary Valve Procedures
•
Peijia Medical Ltd (HKG: 9996) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its second-generation balloon dilation catheter, Taurus Atlas Pro. This non-compliant balloon is designed for percutaneous transluminal valvuloplasty of the pulmonary valve. The Taurus Atlas Pro balloon dilation catheter is…
